Celebrating the discovery of mutated CALR

MPN Research Foundation is proud to celebrate the 10-year anniversary of the identification of CALR as a common driver of MPNs. We funded early work that discovered this MPN driver mutation. Learn more >
MPNRF by the numbers
Total donated dollars
invested in research
$ 0 M
Researchers supported
0
Countries with
supported research
0
Projects funded
0

What is
essential
thrombocythemia
(ET)
?

Essential Thrombocythemia (ET)

Most commonly diagnosed in women over the age of 50, ET is associated with a proliferation of platelet precursors in the bone marrow and complications frequently include blood clotting and/or bleeding.

Learn more about ET

What is
polycythemia vera
(PV)
?

Polycythemia
vera (PV)

The disease is most common in men over the age of 60, but anyone can develop PV. PV patients typically experience an elevated red blood cell count, an elevated platelet count and an enlarged spleen, especially over time.

Learn more about PV

Myelofibrosis (MF)

MF is a chronic blood cancer in which excessive scar tissue forms in the bone marrow and impairs its ability to produce normal blood cells.

Learn more about MF

What is
myelofibrosis
(MF)
?

Patients, clinicians, researchers, and the biotech and pharma industries all have critical roles to play in advancing MPN research and are all important members of the MPNRF community.
Connect with us to be part of our coordinated effort to find new treatments — and eventually cures — for MPNs.

Patients
and Caregivers

Every patient experience is unique and provides new clues for researchers and clinicians.

Researchers
and
Clinicians

In our 24-year history, MPNRF has contributed to some of the most influential MPN research discoveries.

Industry
and
Biopharma

Engage with us to ensure that new therapies have the maximum impact on patient outcomes and quality of life.

Download our Voice of the Patient report

Ready to do more?

Julie and her family joined team MPN and created HikeMF to join the fight against MPNs.

Stay connected

Invest in MPN research

Your investment supports doctors and researchers around the world who are dedicated to finding cures for MPNs.

 INVEST NOW

Join the community
Be the first to know about the latest news and advancements for ET, PV, and MF. Sign up to receive our newsletters and alerts.

Recent news

  • MPN Research Foundation: A legacy of impact

    MPN NEWS | December 4, 2025

    MPN Research Foundation: A legacy of impact Sources Kralovics, R., et al. (2002). Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Experimental Hematology, 30(3), 229–236. Klampfl, T., et al. (2013). Somatic mutations of calreticulin in myeloproliferative neoplasms. The New England Journal of Medicine, 369(25), 2379–2390. Moliterno, A. R.,… Read More »MPN Research Foundation: A legacy of impact

    READ MORE

    Blasts 101 — what they are and where they belong  

    MPN NEWS | October 29, 2025

    Blasts 101 — what they are and where they belong Your body constantly makes new blood cells in the bone marrow, a process called hematopoiesis. Blasts are early, still-developing cells that are in a transitionary stage between stem cells and fully mature blood cells. There are two main types of blast cells that make up… Read More »Blasts 101 — what they are and where they belong  

    READ MORE

    From CALR to the cutting edge: Dr. Ann Mullally’s view of the future of MPN Research

    MPN NEWS | October 28, 2025

    Few scientists have a clearer view of where myeloproliferative neoplasm (MPN) research is headed than Dr. Ann Mullally, MD. As a physician-scientist, Division Chief of Hematology at Stanford, and member of the MPN Research Foundation’s Scientific Advisory Board (SAB), she sits at the crossroads of patient care, clinical trials, and discovery science.  From this vantage… Read More »From CALR to the cutting edge: Dr. Ann Mullally’s view of the future of MPN Research

    READ MORE